0000000000200095

AUTHOR

Ana De La Fuente

showing 4 related works from this author

Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer

2017

Background: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications. In this context, the positron emitter scandium-44 is an attractive alternative for PET imaging. We report the synthesis of [44Sc…

OncologyMalemedicine.medical_specialtytheranostics.Medicine (miscellaneous)Context (language use)SpleenGallium RadioisotopesLutetiumurologic and male genital diseases030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancerHeterocyclic Compounds 1-Ring0302 clinical medicineInternal medicinePositron Emission Tomography Computed TomographyLNCaPmedicineDosimetryHumansRadiometryPharmacology Toxicology and Pharmaceutics (miscellaneous)AgedRadioisotopesUrinary bladderChemistrybusiness.industryDipeptidesProstate-Specific Antigenmedicine.diseaseprostate cancerPSMA-617scandium-44Small intestineProstatic Neoplasms Castration-Resistantmedicine.anatomical_structurePET030220 oncology & carcinogenesisAbsorbed doseRadiopharmaceuticalsNuclear medicinebusinessScandiumResearch PaperHalf-LifeTheranostics
researchProduct

Optimization of Labeling PSMAHBED with Ethanol-Postprocessed 68Ga and Its Quality Control Systems

2017

Radiolabeling of the prostate-specific membrane antigen (PSMA) inhibitor Glu-NH-CO-NH-Lys(Ahx) using the 68Ga chelator HBED-CC (PSMAHBED) allows imaging of prostate cancer lesions because of high expression of PSMA in prostate carcinoma cells and in bone metastases and lymph nodes related to the disease. The aim of this work was to optimize labeling of 68Ga-PSMAHBED using the efficient cation-exchange postprocessing of 68Ga as well as the development of a thin-layer chromatography (TLC)-based quality control system. Methods: Labeling was optimized for online ethanol-postprocessed 68Ga eluate investigating various parameters, such as buffer molarity (0.1-1 M), temperature (25°C-90°C), tracer…

ChromatographyMolar concentrationElutionSilica gelProstate carcinomaClinical routine030218 nuclear medicine & medical imaging03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistryQuality control system030220 oncology & carcinogenesisRadiology Nuclear Medicine and imagingMembrane antigenJournal of Nuclear Medicine
researchProduct

Labeling and preliminary in vivo assessment of niobium-labeled radioactive species: A proof-of-concept study.

2016

Abstract The application of radionuclide-labeled biomolecules such as monoclonal antibodies or antibody fragments for imaging purposes is called immunoscintigraphy . More specifically, when the nuclides used are positron emitters, such as zirconium-89, the technique is referred to as immuno-PET . Currently, there is an urgent need for radionuclides with a half-life which correlates well with the biological kinetics of the biomolecules under question and which can be attached to the proteins by robust labeling chemistry. 90 Nb is a promising candidate for in vivo immuno-PET , due its half-life of 14.6h and low β + energy of E mean =0.35MeV per decay. 95 Nb on the other hand, is a convenient …

Cancer ResearchPathologymedicine.medical_specialtyBiodistributionmedicine.drug_classMetaboliteNiobiumDeferoxamineMonoclonal antibody030218 nuclear medicine & medical imagingImmunoscintigraphy03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineChloridesDrug StabilityIn vivomedicineAnimalsRadiology Nuclear Medicine and imagingTissue DistributionRadioisotopesOxalatesChemistryIn vitroBevacizumab030220 oncology & carcinogenesisIsotope LabelingPositron-Emission TomographyBiophysicsMolecular MedicineSpecific activityFemaleEx vivoHalf-LifeNuclear medicine and biology
researchProduct

Labeling of DOTA-conjugated HPMA-based polymers with trivalent metallic radionuclides for molecular imaging.

2017

Background In this work, the in vitro and in vivo stabilities and the pharmacology of HPMA-made homopolymers were studied by means of radiometal-labeled derivatives. Aiming to identify the fewer amount and the optimal DOTA-linker structure that provides quantitative labeling yields, diverse DOTA-linker systems were conjugated in different amounts to HPMA homopolymers to coordinate trivalent radiometals Me(III)* = gallium-68, scandium-44, and lutetium-177. Results Short linkers and as low as 1.6% DOTA were enough to obtain labeling yields > 90%. Alkoxy linkers generally exhibited lower labeling yields than alkane analogues despite of similar chain length and DOTA incorporation rate. High sta…

lcsh:Medical physics. Medical radiology. Nuclear medicinelcsh:R895-920Gallium-68610 MedizinDOTA-HPMA conjugatesPETBiodistributionTheranostic610 Medical sciencesScandium-44Lutetium-177neoplasmsOriginal ResearchRadiolabelingEJNMMI research
researchProduct